Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Adds FedMed to PPOs Covering BrevaGen

NEW YORK (GenomeWeb News) – Genetic Technologies today said that its wholly owned subsidiary Phenogen Sciences has executed an agreement with preferred provider organization FedMed for access to its network of clinicians and healthcare providers.

The deal is the seventh between GTG and a US PPO, the Australian developer of the BrevaGen breast cancer risk assessment test, said. Last month, it signed agreements with MultiPlan and the Three Rivers Provider Network, and in total, the number of covered lives with access to BrevaGen as an in-network service is more than 102 million, GTG said.

Based in Rockville, Md., FedMed covers more than 40 million lives and has a network of more than 550,000 physicians, 60,000 ancillary care providers, and 4,000 hospitals nationwide. Phenogen is based in Charlotte, NC.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.